ALX looks to surprise again
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
Tempest’s pivotal amezalpat conundrum
How does the micro-cap biotech now finance a 700-patient phase 3 study?
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
Can Wee1 be both alive and dead? Schrödinger hopes so
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
EHA 2024 – Nurix and BeiGene’s degraders shine
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
